University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

I-Chow Hsu, M.D.

Radiation cancer specialist

Dr. I-Chow (Joe) Hsu is a radiation oncologist with special expertise in brachytherapy, a form of radiotherapy where a radioactive source is placed inside or next to the area requiring treatment such as localized prostate cancer. Hsu has special research interests in the application of brachytherapy and hyperthermia in genitourinary and gynecologic cancers. He is an active member of numerous professional medical societies including the American Society for Therapeutic Radiology, American Brachytherapy Society and Society for Thermal Medicine. He also chairs the brachytherapy committee of the Radiation Therapy Oncology Group.

Hsu earned a medical degree at the Johns Hopkins School of Medicine and completed a residency in radiation oncology at Columbia-Presbyterian Medical Center in New York. He is an associate professor of radiation oncology at the University of California, San Francisco. Hsu is certified in radiation oncology by the American Board of Radiology.

Clinics

Radiation Oncology at Mount Zion
1600 Divisadero St., Basement Level
San Francisco, CA 94143-1708
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-9807
Fax: (415) 353-9884

Hours: Monday to Friday
7 a.m. – 6 p.m.

Radiation Oncology at Parnassus
505 Parnassus Ave, Room L-75
San Francisco, CA 94143-0226
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-8335
Fax: (415) 353-7281

Hours: Monday to Friday
8 a.m. – 4:30 p.m.

Conditions & Treatments

More about I-Chow Hsu

Additional Languages

Chinese
Mandarin

Education

John Hopkins School of Medicine 1991

Residencies

San Bernadino Medical Center, Transitional Intern 1992

Fellowships

Columbia-Presbyterian Medical, Radiation Oncology 1995

Selected Research and Publications

  1. Hsu IC, Hunt D, Straube, W, Pouliot J, Cunha A, Krishnamurthy D, Sandler H. Dosimetric Analysis of Radiation Therapy Oncology Group 0321: The Importance of Urethral Dose. Practical Radiation Oncology. 2014; 4:27-34.
  2. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
  3. Myerson RJ, Moros EG, Diederich CJ, Haemmerich D, Hurwitz MD, Hsu IC, McGough RJ, Nau WH, Straube WL, Turner PF, Vujaskovic Z, Stauffer PR. Components of a hyperthermia clinic: Recommendations for staffing, equipment, and treatment monitoring. Int J Hyperthermia. 2014 Feb; 30(1):1-5.
  4. Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50.
  5. Salgaonkar VA, Rieke V, Ozhinsky E, Prakash P, Plata J, Kurhanewicz J, Hsu IC, Diederich CJ. Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MRI-guided endorectal high intensity focused ultrasound ablation array. J Acoust Soc Am. 2013 Nov; 134(5):4180.
  6. Pinnaduwage DS, Cunha JA, Weinberg V, Krishnamurthy D, Nash M, Hsu IC, Pouliot J. A dosimetric evaluation of using a single treatment plan for multiple treatment fractions within a given applicator insertion in gynecologic brachytherapy. Brachytherapy. 2013 Sep-Oct; 12(5):487-94.
  7. Hsu IC, Hunt D, Straube W, Pouliot J, Cunha A, Krishnamurthy D, Sandler H. Dosimetric analysis of radiation therapy oncology group 0321: The importance of urethral dose. Pract Radiat Oncol. 2014 Jan-Feb; 4(1):27-34.
  8. Cury FL, Hunt D, Roach M, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C. Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Jun 1; 119(11):1999-2004.
  9. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
  10. Pejavar S, Yom SS, Hwang A, Speight J, Gottschalk A, Hsu IC, Roach M, Xia P. Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat. 2013 Jun; 12(3):199-206.
  11. Siauw T, Cunha A, Berenson D, Atamturk A, Hsu IC, Goldberg K, Pouliot J. NPIP: A skew line needle configuration optimization system for HDR brachytherapy. Med Phys. 2012 Jul; 39(7):4339-46.
  12. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 1; 85(2):370-7.
  13. Abdel-Wahab M, Mahmoud O, Merrick G, Hsu IC, Arterbery VE, Ciezki JP, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y. ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancer. J Am Coll Radiol. 2012 Apr; 9(4):233-8.
  14. Yamada Y, Rogers L, Demanes DJ, Morton G, Prestidge BR, Pouliot J, Cohen GN, Zaider M, Ghilezan M, Hsu IC. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy. 2012 Jan-Feb; 11(1):20-32.
  15. Moran BJ, DeRose P, Hsu IC, Abdel-Wahab M, Arterbery VE, Ciezki JP, Frank SJ, Mohler JL, Rosenthal SA, Rossi CJ, Yamada Y, Merrick GS. ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2011 Dec; 34(6):636-47.
  16. Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21; 56(24):7767-75.
  17. Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M, Hsu IC. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy. 2012 Sep-Oct; 11(5):348-53.
  18. Ciezki JP, Hsu IC, Abdel-Wahab M, Arterbery VE, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer. Clin Oncol (R Coll Radiol). 2012 Feb; 24(1):43-51.
  19. Siauw T, Cunha A, Atamtürk A, Hsu IC, Pouliot J, Goldberg K. IPIP: A new approach to inverse planning for HDR brachytherapy by directly optimizing dosimetric indices. Med Phys. 2011 Jul; 38(7):4045-51.
  20. Wootton JH, Prakash P, Hsu IC, Diederich CJ. Implant strategies for endocervical and interstitial ultrasound hyperthermia adjunct to HDR brachytherapy for the treatment of cervical cancer. Phys Med Biol. 2011 Jul 7; 56(13):3967-84.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.